Estrogen Receptor Alpha Phosphorylated at Tyrosine 537 is Associated with Poor Clinical Outcome in Breast Cancer Patients Treated with Tamoxifen

Hormones and Cancer

Volumn 1, Issue 4, 2010, Pages 215-221

  Skliris, Georgios P ^a,b   Nugent, Zoann ^b   Watson, Peter H ^b,c   Murphy, Leigh C ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Breast cancer; Endocrine therapy; Estrogen receptor; Immunohistochemistry; Phosphorylation; Tissue microarrays; Tyrosine 537

Indexed keywords

ANTIBODY; ESTROGEN RECEPTOR ALPHA; TAMOXIFEN; TYROSINE;

ADULT; ARTICLE; BREAST CANCER; CANCER RELAPSE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY; TREATMENT OUTCOME; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHOSPHORYLATION; RECEPTOR, ERBB-2; TAMOXIFEN; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TYROSINE;

EID: 78650199252     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-010-0049-z     Document Type: Article

References (35)

1. Arnold S, Obourn J, Jaffe H, Notides A (1995) Phosphorylation of the human estrogen receptor on tyrosine 537 in vivo and by Src family tyrosines in vitro. Mol Endocrinol 9: 24-33.
2. Marquez DC, Lee J, Lin T, Pietras RJ (2001) Epidermal growth factor receptor and tyrosine phosphorylation of estrogen receptor. Endocr 16(2): 73-81.
3. Pietras R, Arboleda J, Reese D, Wongvipat N, Pegram M, Ramos L, Gorman C, Parker M, Sliwkowski M, Slamon D (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone independent growth in human breast cancer cells. Oncogene 10(12): 2435-2446.
4. Zhang QX, Borg A, Wolf DM, Oesterreich S, Fuqua SA (1997) An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res 57(7): 1244-1249.
5. Watson P, Snell L, Parisien M (1996) The NCIC-Manitoba Breast Tumor Bank: a resource for applied cancer research. CMAJ 155: 281-283.
6. Snell L, Watson P (2006) Breast tissue banking: collection, handling, storage, and release of tissue for breast cancer research. Meth Mol Med 120: 3-24.
7. Skliris GP, Nugent ZJ, Rowan BG, Penner CR, Watson PH, Murphy LC (2010) A phosphorylation code for oestrogen receptor-alpha predicts clinical outcome to endocrine therapy in breast cancer. Endocr Relat Cancer 17(3): 589-597.
8. Skliris GP, Rowan BG, Al-Dhaheri M, Williams C, Troup S, Begic S, Parisien M, Watson PH, Murphy LC (2009) Immunohistochemical validation of multiple phospho-specific epitopes for estrogen receptor alpha (ERalpha) in tissue microarrays of ERalpha positive human breast carcinomas. Breast Cancer Res Treat 118(3): 443-453.
9. Weitsman G, Li L, Skliris G, Davie J, Ung K, Curtis-Snell L, Tomes L, Watson P, Murphy L (2006) Estrogen receptor-alpha phosphorylated at Serine 118 is present at the promoters of estrogen-regulated genes and is not altered due to Her2 over-expression. Cancer Res 66: 10162-10170.
10. Weigel N, Moore N (2007) Steroid receptor phosphorylation: a key modulator of multiple receptor functions. Mol Endocrinol 21: 2311-2319.
11. Murphy LC, Cherlet T, Adeyinka A, Niu Y, Snell L, Watson P (2004) Phospho-serine-118 estrogen receptor-alpha detection in human breast tumors in vivo. Clin Cancer Res 10: 1354-1359.
12. Gee J, Robertson J, Gutteridge E, Ellis I, Pinder S, Rubini M, Nicholson R (2005) Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 12(Suppl 1): S99-S111.
13. Yamashita H, Nishio M, Toyama T, Sugiura H, Kondo N, Kobayashi S, Fuji Y, Iwase H (2008) Low phosphorylation of estrogen receptor alpha (ER{alpha}) serine 118 and high phosphorylation of ER{alpha} serine 167 improve survival in ER-positive breast cancer. Endocr Relat Cancer 15: 755-763.
14. Holm C, Kok M, Michalides R, Fles R, Koornstra RH, Wesseling J, Hauptmann M, Neefjes J, Peterse JL, Stal O et al (2009) Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer. J Pathol 217(3): 372-379.
15. Jiang J, Sarwar N, Peston D, Kulinskaya E, Shousha S, Coombes R, Ali S (2007) Phosphorylation of estrogen receptor-alpha at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients. Clin Cancer Res 13: 5769-5776.
16. Weis K, Ekena K, Thomas J, Lazennec G, Katzenellenbogen B (1996) Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol Endocrinol 10: 1388-1398.
17. Arnold SF, Melamed M, Vorojeikina DP, Notides AC, Sasson S (1997) Estradiol-binding mechanism and binding capacity of the human estrogen receptor is regulated by tyrosine phosphorylation. Mol Endocrinol 11(1): 48-53.
18. Arnold SF, Notides AC (1995) An antiestrogen: a phosphotyrosyl peptide that blocks dimerization of the human estrogen receptor. Proc Natl Acad Sci USA 92(16): 7475-7479.
19. Shiau A, Barstad D, Loria P, Cheng L, Kushner P, Agard D, Greene G (1998) The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95: 927-937.
20. Nettles KW, Bruning JB, Gil G, Nowak J, Sharma SK, Hahm JB, Kulp K, Hochberg RB, Zhou H, Katzenellenbogen JA et al (2008) NFkappaB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses. Nat Chem Biol 4(4): 241-247.
21. Reid G, Hubner M, Metivier R, Brand H, Denger S, Manu D, Beaudouin J, Ellenberg J, Gannon F (2003) Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell 11(1): 695-707.
22. Metivier R, Penot G, Hubner M, Reid G, Brand H, Kos M, Gannon F (2003) Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115(6): 751-763.
23. Dutertre M, Smith C (2003) Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains. Mol Endocrinol 17: 1296-1314.
24. Kobayashi Y, Kitamoto T, Masuhiro Y, Watanabe M, Kase T, Metzger D, Yanagisawa J, Kato S (2000) p300 mediates functional synergism between AF-1 and AF-2 of estrogen receptor alpha and beta by interacting directly with the N-terminal A/B domains. J Biol Chem 275: 15645-15651.
25. Campbell EJ, McDuff E, Tatarov O, Tovey S, Brunton V, Cooke TG, Edwards J (2008) Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer. Br J Cancer 99(11): 1769-1774.
26. Newby J, Johnston S, Smith I, Dowsett M (1997) Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 3: 1643-1651.
27. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M (2005) Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 23(11): 2469-2476.
28. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, Barone MV, Ametrano D, Zannini MS, Abbondanza C et al (2000) Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J 19(20): 5406-5417.
29. Varricchio L, Migliaccio A, Castoria G, Yamaguchi H, de Falco A, Di Domenico M, Giovannelli P, Farrar W, Appella E, Auricchio F (2007) Inhibition of estradiol receptor/Src association and cell growth by an estradiol receptor alpha tyrosine-phosphorylated peptide. Mol Cancer Res 5(11): 1213-1221.
30. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L, Hung MC (2001) Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3(9): 802-808.
31. Aleksic T, Chitnis MM, Perestenko OV, Gao S, Thomas PH, Turner GD, Protheroe AS, Howarth M, Macaulay VM (2010) Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells. Cancer Res 70(16): 6412-6419.
32. Wang YN, Yamaguchi H, Hsu JM, Hung MC (2010) Nuclear trafficking of the epidermal growth factor receptor family membrane proteins. Oncogene 29(28): 3997-4006.
33. Barone I, Brusco L, Fuqua SA (2010) Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res 16(10): 2702-2708.
34. Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O'Connell P et al (2000) A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res 60(15): 4026-4029.
35. Cui Y, Zhang M, Pestell R, Curran EM, Welshons WV, Fuqua SA (2004) Phosphorylation of estrogen receptor alpha blocks its acetylation and regulates estrogen sensitivity. Cancer Res 64(24): 9199-9208.